A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis

Cancer Control

Volumn 24, Issue 5, 2017, Pages

  Richard, Kaja ^a   Weslow, Jacqueline ^a   Porcella, Stephanie L ^a   Nanjappa, Sowmya ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

encephalitis; immune related Adverse events; neurotoxicity; nivolumab; non small cell lung cancer

Indexed keywords

CARBOPLATIN; COTRIMOXAZOLE; DEXAMETHASONE; FOLIC ACID; HALOPERIDOL; METHYLPREDNISOLONE SODIUM SUCCINATE; NIVOLUMAB; PACLITAXEL; RISPERIDONE; THIAMINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CASE REPORT; CLAUSTROPHOBIA; CLINICAL ARTICLE; ECCHYMOSIS; ELECTROENCEPHALOGRAM; ENCEPHALITIS; HALLUCINATION; HUMAN; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NON SMALL CELL LUNG CANCER; ORBIT FRACTURE; PHYSICAL EXAMINATION; RESTLESSNESS; SEIZURE; STAPHYLOCOCCUS INFECTION; STEREOTACTIC RADIOSURGERY; STEROID THERAPY; CHEMICALLY INDUCED; COMPLICATION; LUNG TUMOR; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; ENCEPHALITIS; HUMANS; LUNG NEOPLASMS; MALE;

EID: 85038579439     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/1073274817729069     Document Type: Article

References (15)

1. Keating GM. Nivolumab: a review in advanced squamous non-small cell lung cancer. Drugs. 2015;75(16):1925–1934.
2. Brahmer J, Reckamp KL, Baas P. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
3. Brahmer JR, Drake CG, Wollner I. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–3175.
4. Boyd K, Kalladka D, Overell J. Ipilimumab induced encephalitis: a case report. Immunome Res. 2015;11:092.
5. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016;29(6):806–812.
6. Wang C, Thudium KB, Han M. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856.
7. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
8. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111(12):2214–2219.
9. Bot I, Blank CU, Boogerd W. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13(4):278–280.
10. Williams TJ, Benavides DR, Patrice KA. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928–933.]
11. Maur M, Tomasello C, Frassoldati A. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012;30(6):e76–78.
12. Bompaire F, Mateus C, Taillia H. Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs. 2012;30(6):2407–2410.
13. Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016.
14. Venkatesan A, Benavides DR. Autoimmune encephalitis and its relation to infection. Curr Neurol Neurosci Rep. 2015;15(3):3.
15. US Department of Health and Human Services, National Cancer Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). v4.0. http://ctep.cancer.gov. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed July 5, 2017.